TY - CHAP M1 - Book, Section TI - Cancer-Associated Thrombosis A1 - Casteel, Kelly A. A1 - Kroll, Michael H. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. PY - 2022 T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSVenous thromboembolism (VTE) is common in patients with cancer and contributes to their morbidity and mortality.All hospitalized patients with cancer should be given pharmacologic thromboprophylaxis unless there is a contraindication.High-risk ambulatory patients with cancer receiving outpatient chemotherapy can be considered candidates for receiving prophylactic-dose apixaban or rivaroxaban.Cancer-associated VTE treatment with anticoagulation is associated with a higher rate of recurrence and bleeding compared with non–cancer-related VTE, so one must fastidiously review the risk–benefit ratio for each patient before beginning anticoagulation.Cancer-associated thrombotic microangiopathy is not caused by ADAMTS-13 autoantibodies and does not improve with plasma exchange.Routine anticoagulation or antiplatelet therapy for cancer patients with atrial fibrillation or coronary artery disease appears to be safe. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1190840223 ER -